Clinical Trials on Recurrent Pancreatic Ductal Adenocarcinoma

Total 3204 results

National Cancer Institute (NCI)

Completed

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder | Adenocarcinoma of the Gallbladder | Adenocarcinoma With... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma | Recurrent Colorectal Carcinoma | Colorectal... and other conditions

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Stage IV Pancreatic Cancer AJCC v6 and v7 | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Active, not recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States, Singapore, Australia
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Rambam Health Care Campus

Unknown

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Lung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
Radboud University Medical Center

Completed

Continuous Monitoring on the General Ward

Sepsis | Hypertension | Arthritis | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma

United States
Peking Union Medical College Hospital

Recruiting

Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

China
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene

Withdrawn

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
University of Roma La Sapienza

Terminated

Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients (PaCANOD)

Diabetes Complications | Diabetes Mellitus, Adult-Onset | Carcinoma, Pancreatic Ductal | Pancreatic Neoplasm

Italy
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Fudan University

Unknown

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Yonsei University

Withdrawn

Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy

Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)

Completed

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Gritstone bio, Inc.

Completed

A Study of Personalized Neoantigen Cancer Vaccines

Colorectal Cancer | Non Small Cell Lung Cancer | Gastroesophageal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Completed

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
University Hospital, Montpellier

Not yet recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
National Cancer Institute (NCI)

Completed

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Pharmacyclics LLC.

Completed

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Pancreatic Cancer | Exocrine Pancreatic Cancer | Ductal Adrenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
Yonsei University

Unknown

Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery

Pancreatic Cancer or Distal CBD Cancer

Korea, Republic of
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University; American...

Terminated

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Stage I Pancreatic Cancer AJCC v8 | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIA Melanoma | Stage IIIB Melanoma and other conditions

United States
Yale University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage I Pancreatic Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Lung Cancer | Lung Cancer Metastatic | Lung Adenocarcinoma | Lung Cancer Stage IV | Recurrent Lung Adenocarcinoma | Recurrent Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
National Cancer Institute (NCI)

Terminated

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer

United States
Xian-Jun Yu

Completed

Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China

Clinical Trials on Recurrent Pancreatic Ductal Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations